AI assistant
Ipsen — AGM Information 2018
May 30, 2018
1449_iss_2018-05-30_75fe6a70-489b-4b44-b2c7-ce851ff263e6.pdf
AGM Information
Open in viewerOpens in your device viewer
Combined Shareholders' Meeting of IPSEN S.A. held on 30 May 2018
Adoption of all resolutions submitted to the vote of Shareholders
Paris (France), 30 May 2018 - The Combined Shareholders' Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was held today, in the presence of the members of the Board of Directors and the Group's Executive Management team.
The Shareholders' Meeting approved all the resolutions submitted by the Board of Directors and in particular, the distribution of a dividend of €1.00 per share to be paid on 6 June 2018 (ex-dividend date 4 June 2018).
The Shareholders' Meeting also approved the renewal of Ms. Anne Beaufour as a director, as well as the appointments as directors of M. Philippe Bonhomme, to replace MAYROY S.A., and of M. Paul Sekhri and M. Piet Wigerinck. The Board welcomed the newly-appointed directors.
Ms. Hélène Auriol-Potier, M. Hervé Couffin and M. Pierre Martinet did not wish to renew their mandate. The Board also noted today the resignation of M. Christophe Verot, as a director. The Board thanked them for their major contributions to the Board of Directors.
Following the Shareholders' Meeting, the new Board of Directors is comprised of 12 members, five of whom are women.
During the Meeting, David Meek, Chief Executive Officer and Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer, focused on the group strategy, highlights and financial results for 2017, and also confirmed the objectives and guidance for 2018.
About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com
For further information:
Media
Ian Weatherhead Vice President, Corporate External Communications +44 (0) 1753 627733 [email protected]
Financial Community
Eugenia Litz Vice President, Investor Relations +44 (0) 1753 627721 [email protected]
Brigitte Le Guennec Senior Manager, Global External Communications +33 (0)1 58 33 51 17 [email protected]
Myriam Koutchinsky Investor Relations Manager +33 (0)1 58 33 51 04 [email protected]